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Abstract
Background: The interleukin-28B gene (IL28B) locus has been associated with host resistance to hepatitis C virus (HCV)
infection and response to PEG-IFN/RBV treatment in western populations. This study was to determine whether this gene
variant is also associated with spontaneous clearance of HCV infection, treatment response and IL-28B protein production in
Chinese patients.
Methods: We genotyped IL28B genetic variations (rs12980275, rs8103142, rs8099917 and rs12979860) by pyrosequencing
DNA samples from cohorts consisting of 529 subjects with persistent HCV infection, 196 subjects who cleared the infection,
171 healthy individuals and 235 chronic HCV patients underwent IFN/RBV treatment. The expression of IL-28B were
measured by ELISA and RT-PCR.
Results: We found that the four IL28B variants were in complete linkage disequilibrium (r2=0.97–0.98). The rs12979860 CC
genotype was strongly associated with spontaneously HCV clearance and successful IFN/RBV treatment compared to the
CT/TT. IL-28B levels in persistent HCV patients were significantly lower than subjects who spontaneously resolved HCV and
healthy controls and were also associated with high levels of ALT (alanine aminotransferase) and AST (aspartate
aminotransferase). IL-28B levels were also significantly lower in individuals carrying T alleles than CC homozygous.
Conclusions: Thus, the rs12979860-CC variant upstream of IL28B gene is associated with spontaneous clearance of HCV,
susceptible to IFN/RBV treatment and increased IL-28B levels in this Chinese population.
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Introduction
Hepatitis C virus (HCV) infection is a major health problem
worldwide [1]. There are two distinct outcomes of an acute HCV
infection; approximately 30% of HCV-infected individuals will
spontaneously resolve HCV infection, developing robust protec-
tive immunity against reinfection. Among the remaining 70%
patients, only half of them can be successfully treated with
pegylated-interferona (pegIFN) plus ribavirin (RBV) [2–5] and the
rest respond poorly to the treatment and will develop chronic
infection which is the major cause of cirrhosis and hepatocellular
carcinoma [6–8].
Thus, an understanding of the difference in host resistance to
HCV infection and in response to treatment would be clinically
important and may lead to novel therapeutic interventions.
The influence of viral genotype, load, sex and age on the natural
course of HCV infection and outcomes have been evaluated with
contradictory results [9]. Host innate and adaptive immunity also
has a profound impact on HCV infection [10]. It has been
suggested that chronic HCV infection may result from a impaired
host immunity in particular cellular immune response against
HCV [11–13]. It was recognized that genetic factor(s) may be
responsible for the distinct consequences of HCV infection in
different hosts [14,15]. Interferons (IFNs) are the key cytokines
produced by immune cells and play a pivotal role in natural host
defense against HCV infection [16]. IFNa by far is the most
effective means for clinical treatment of HCV infection. However,
whether IFNs are the determining factor in the different outcomes
of HCV infection is unknown until recently GWAS demonstrated
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37054that IL28B genetic variations are closely associated with host
defence against HCV infection [17].
IL28B gene encodes cytokine IL-28B (IFNl3) [18]. It belongs to
the type III IFN family, also known as IFN-lamdas (IFNls) which
also includes IL-29 (IFNl1) and IL-28A (IFN l2) [19,20]. The
genes of IFNls are clustered on human chromosome 19. IL-28B is
the latest member of IFN family and plays a critical role in clearing
viral infections [21,22]. It is mainly produced by macrophages and
dendritic cells (DCs) in response to the stimuli of viral proteins or
toll-like receptor (TLR) agonists [23]. IL-28B plays an important
role in antiviral responses including HCV infection [17]. IFNls
signal via common type III interferon receptors consisting of IL-
10R2 and IL-28R subunit and trigger JAK-STAT (Janus kinase-
signal transducers and activators of transcription) pathway to
induce the expression of IFN-stimulate genes (ISGs) [16]. These
ISG products can subsequently suppress a wide range of viral
replications and protein synthesis including hepatitis B and C virus
[24]. IFNl receptors are expressed on a variety of cells,
predominantly the liver and epithelial cells [19,25], suggesting
that they may have a profound impact on liver function.
Recently, several genome-wide association studies (GWAS) have
independently demonstrated that IL28B variations, in particular
rs12979860, are strongly associated with host natural defense
against HCV infections in western populations [17]. They are also
associated with HCV patients’ response to pegylated-IFNa and
RBV treatment in different populations [26,27]. Thus, IL28B
polymorphisms may represent determining factors in both host
resistance/susceptibility to HCV infection and treatment, which
may provide a genetic explanation for the different outcomes of
HCV infection in distinct hosts. The gene frequency of C allele in
rs12979860 is much higher in Chinese than Europe population
(95.5% vs 68%) [17]. However, the influence and the cause-effect
of the IL28B variant on HCV infection and IL-28B protein
production in Chinese population is unknown.
The aim of this study was to explore the impact of the IL28B
variations (rs12979860) on the clinical outcome of HCV infection,
the treatment response and the mRNA and serum protein levels of
IL-28B in a large Chinese Han population with HCV infection. A
better understanding of the natural host immune defense against
HCV will enhance our ability to treat HCV infection.
Materials and Methods
Patients
A total 896 Chinese Han individuals were enrolled in this study,
all attended the ‘‘Epidemiological investigation of Hepatitis C
virus infection in FuYu country of Jilin Province’’ in the First
Hospital of Jilin University from 2009–2010. This study included
529 subjects with persistent HCV infection, 196 individuals who
spontaneously cleared the virus, and 171 healthy controls. The
persistent infection group included 340 male and 189 female HCV
patients. All the subjects were human immune deficiency virus
negative, anti-HCV positive, and HCV RNA positive in serum.
The group showing spontaneous viral clearance comprised 101
males and 95 females who were anti-HCV positive and HCV-
RNA negative. The healthy controls included 85 men and 86
women who had no medical history of any liver disease and were
considered as representative of the normal frequencies of this study
in the Chinese population.
Our study design is based on population-based sample. Healthy
control population selection criteria: the same region, Han
population, and no past liver disease history by routine physical
examination, liver function, abdominal Ultrasound, no abnormal
HBV and HCV tests. Equal number of men and women were in
the healthy control group.
235 chronic HCV patients who underwent the IFN/RBV
treatment regimen were also included in the study. These patients
are receiving recombinant interferon-a2b (500,0000 IU, 3times/
week, Bei Jing Kavin Technology Share-holding Co, Ltd. China)
and oral ribavirin (,60 kg, 800 mg/day; 60–75 kg, 1000 mg/
day; and .75 kg,1200 mg/day). Patients with decompensated
liver disease, hepatoma, co-infection with hpatitis B virus or with
human immunodeficiency virus, with apparent autoimmune
hepatitis and alcoholic liver disease were excluded from this
cohort. The definitions of response to treatment were undetectable
serum HCV-RNA at 4 week after starting treatment as Rapid
virologic response (RVR), at least two-log10 reduction of viral load
at week 12 after starting treatment as early virologic response
(EVR) and undetectable virus at week 12 after starting treatment
as complete early virologic response (cEVR).
To participate in the study, written informed consent for all
testing was obtained from all individuals, and the study protocol
was approved by the hospital ethics committee of the First
Hospital of Jilin University.
The participants completed questionnaires and underwent
comprehensive medical examinations including liver ultrasound
examination, anthropometric, blood pressure and blood tests.
Blood samples were collected for biochemistry, liver function and
serum lipids tests in the Clinical Laboratory of the First Hospital of
Jilin University. The tests for biochemistry, liver function (ALT/
AST) and serum lipids were performed using a Synchron LXH20
autoanalyser (Beckman Coulter, Brea, CA, USA). The levels of
anti-HCV, HBsAg and human immune deficiency virus were
measured using an Abbott ARCHITECT i2000SR and HCV-
RNA levels were quantified using the Roche Amplicor HCV
Monitor or Roche Taqman HCV test (Roche Diagnostics,
Grenzach, Germany). HCV genotype was performed by multi-
color fluorescence PCR with HCV RNA genotype kit (BioAssay
Science & Technology Co. Ltd,China).
IL28B genotyping
Human genomic DNA was extracted from peripheral blood
cells by a genomic DNA purification kit (Promega Co., USA).
Genotyping of the rs12979860, rs12980275, rs8103142 and
rs8099917 was performed using a pyrosequencing method,
according to the protocol of the manufacturer (PyroMark ID
Pyrosequencing machine, QIAGEN). The primers for PCR were
rs12979860: forward 59-ATTCCTGGACGTGGATGGG TAC-
39, reverse 59-biotin-AGCGCGGAGTGCAATTCA-39; rs809
9917: forward 59-TTGTCACTGTTCCTCCTTTTGTTT-39,
reverse 59-biotin-TGGGAGAATGCAAATGAGAGATA-39;r s
8103142: forward 59- Biotin-AGAAGGTGAAGGGGCCACTA
-39, reverse 59- CTGTGCCTTTGCTGTCTAGGA -39; rs129
80275: forward 59-GCCAGTCTCAAAAGAACAAATGC-39,
reverse 59-biotin-CTACCCCGGCAAATATTTAGACA-39. Se-
quence primers for pyrosequencing analysis were rs12979860: 59-
AGCTCCCCGAAGGCG- 39; rs8099917: 59-TCCTTTCTG-
TGAGCAAT-39; rs8103142: 59-TGCTG A AGGACTGCA-39;
rs12980275: 59-TGAGAGAAGTCAAATTCCT-39.
IL-28B ELISA
The serum IL-28B levels were determined with an ELISA Kit
specific for IL-28B (Human l3 IFN ELISA Kit, Catalogue
number:I153-00, GBD Ltd. USA). The ELISA was carried out
according to the manufacturer’s instructions and the samples were
measured in an ELISA-reader (EppendorfH BioPhotometer,
Germany) at 450 nm. The sensitivity of IL-28B ELISA was
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ml. The intraassay coefficient of variation was 3.7%, whereas that
of the interassay variation was 5.2%.
Quantitative real-time PCR
Peripheral blood mononuclear cells (PBMCs) were isolated from
74 subjects (48 persistent infection patients; 17 healthy individuals;
9 spontaneous clearance individuals) using Lymphocytes Separat-
ing Solution (DingGuo Biotechnology company, DH184-1). Total
RNA extracted using trizol (Invitrogen) and cDNA was synthe-
sized using random hexamers and SuperScript III Reverse
Transcriptase (Invitrogen). Quantitative RT-PCR was performed
using SYBR green (Realtime PCR MasterMix QPK-201,
TOYOBO) on a 7300 Real-Time PCR System (Applied
Biosystems, USA). The expression levels of IL28B mRNA were
normalized to median expression of GAPDH. Primers used were:
IL28A/B: forward 59-CTG CCA CAT AGC CCA GTT CAA
GT-39, reverse 59-ACT CTT CTA AGG CAT CTT TGG CCC-
39), GAPDH: forward 59-GAA GGT GAA GGT CGG AGTC-39,
reverse 59-GAA GAT GGT GAT GGG ATT TC-39. The person
performing gene expression analysis was blinded to the
rs12979860 genotype.
Statistics Analysis
Continuous variables were presented as mean (standard
deviation) or median (interquartile), while categorical variables
were expressed as frequencies (%). Differences between continuous
variables were evaluated by means of the Student’s t test or
ANOVA. Differences between categorical variables were assessed
using the Pearson Chi-square test. The chi-square G test
‘‘Goodness of Fit’’ was employed to verify whether the proportions
of the polymorphism were distributed in the controls and HCV
infection subjects in accordance with the Hardy-Weinberg
equation. The existence of differences in allelic and genotypic
frequencies between groups was assessed by Chi-square test.
Stepwise logistic regression analysis with a forward approach was
used to verify whether IL28B rs12979860 C/T polymorphism
could be considered a predictor of the HCV spontaneous
clearance. IL28B serum protein expression data was skewed
distribution. Even after transforming the data was still not normal
distribution so that we used non-parametric test methods for
statistical analysis and the median and interquartile range for
illustration. Prior to the analysis, the outlier (one) has been
removed. The odds ratio (OR) with 95% confidence intervals
(95%CI) were calculated using the same analysis. Pairwise linkage
disequilibrium and r2 between SNPs were calculated by PLINK
software. P-value ,0.05 was considered a significant difference.
Statistical analysis of data was performed using the SPSS software
package 18.0 (SPSS Inc. USA).
Results
896 Chinese subjects were involved in this study, including 529
subjects with persistent HCV infection, 196 subjects who cleared
the infection and 171 healthy controls. The characteristics of the
subjects and their demographic data, viral genotype, viral load and
HBsAg status are summarized in Table 1.
The frequencies of the key gene polymorphisms of IL28B;
rs12979860, rs8099917, rs8103142 and rs12980275 were investi-
gated in 303 subjects with persistent infection and 96 individuals
who spontaneously cleared the virus (data not shown). The linkage
disequilibrium (LD) and haplotype analysis with the four SNPs
were performed. The result shows that these SNPs were in
complete LD (D9=0.99–1; r
2=0.97–0.98), therefore, the
rs12979860 was selected as a tag SNP in the subsequent studies.
The distribution of the alleles of rs12979860 was in accordance
with the Hardy-Weinberg equilibrium in this study (P=0.51). We
confirmed that the rs12979860 C allele frequency in this healthy
Chinese population was 95%. The C allele was significantly lower
in the persistent infection group (95.3%) than in the clearance
group (97.7%) (Tab.1). However, the frequency of the T allele was
greater among individuals of the persistent infection group than
those of the clearance group (4.7% vs 2.3%; P=0.04) (Tab. 1).
We further determined the association of the gene variants with
spontaneous viral clearance by logistic regression (Tab. 2). Since
there were fewer individuals with TT genotype of rs12979860 in
this study we combined TT with TC genotype together for
statistical analysis. As shown in Tab. 2, spontaneous HCV
clearance was more common in subjects carrying the CC genotype
than CT/TT genotype (P=0.04, OR=2.12, 95% CI=1.01–
4.42). The influence of sex and HBV co-infection was also
determined by logistic regression (Tab. 2). Sex differences in the
rate of spontaneous viral clearance were also observed; females
appeared to be more effective in spontaneous viral clearance than
males (P=0.002). HBsAg status was also associated with
spontaneous viral clearance (HBsAg negative vs positive:
P=0.001, OR=2.85, 95% CI=1.56–5.22 and male vs female:
P=0.002, OR=1.72, 95% CI=1.23–2.41). (Tab. 2).
The correlation between rs12979860 SNPs and virus load in
chronic HCV subjects was further analysised. There was no
association between IL-28B genotype and virus load in the whole
patients (including genotype 1b or 2a), (data not shown). We did
the test of interaction between viral genotype and IL28B genotype
by Factorial design ANOVA, there is not statistical significance
(P=0.77).
The causative effect of rs12979860 variants on host resistance/
susceptiblity to HCV infection is currently unknown. One
possibility is that this gene variant upstream of the IL28B gene
may affect IL-28B protein production. We then determined and
compared the IL-28B levels in persistent, clearance and healthy
control groups by ELISA. The IL-28B expression levels were
comparable between the healthy control and clearance groups
(Fig. 1A). However, the levels of IL-28B were markedly reduced in
the persistent group compared to the spontaneous clearance and
healthy control groups (Fig. 1A, persistent vs clearance, P=0.003;
persistent vs healthy control, P=0.04). When stratified with
respect to rs12979860 genotypes in overall subjects, IL-28B levels
were significantly higher in CC homozygous than TT/TC home-
or heterozygous (P=0.02) (Fig. 1B). This was also the case in
spontaneous clearance group (P=0.013) but not in the healthy
control or persistent groups (Fig. 1C). We also determined the
mRNA levels of IL28A/B in PBMCs from different subjects by
qRT-PCR. Our results showed that similar to the protein data in
Fig. 1A and B, the levels of IL-28A/B mRNA were markedly
reduced in the persistent group compared to the healthy control
group (Fig.S2.A, persistent vs healthy control, P,0.001). When
stratified with respect to rs12979860 genotypes, IL-28A/B levels
were significantly higher in CC homozygous than TT/TC home-
or heterozygous (P,0.001) (Fig. S2.B).
Transaminase levels indirectly reflect the liver function and host
immune activation [28]. We next determined the levels of
transaminase and their association with IL28B gene variants and
the levels of serum IL-28B in chronic HCV subjects.
We assessed and compared the transaminase levels among the
896 subjects with persistent, cleared HCV infection or the healthy
controls. We confirmed that the levels of ALT, AST and GGT
were significantly higher in subjects with chronic HCV infection
IL28B Genetic Variation of Chinese HCV Patients
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controls (P,0.05) (Tab. 1). We further associated the levels of
transaminase with IL28B variants in patients with persistent HCV
infection (Fig. 2). The levels of AST were significantly higher in the
patients carrying the rs12979860 T allele than the CC homozy-
gous in the persistent group (P=0.02, Fig. 2). However, no
significant difference in their levels of ALT or GGT between CC
and TC/TT carriers was found (data not shown).
The correlation between the levels of serum IL-28B and
transaminase was also determined in 146 chronic HCV patients
with high (ALT:.50 IU/ml; AST.40 IU/ml) or normal (AL-
T:#50 IU/ml; AST:#40 IU/ml) levels of transaminase. As
shown in Fig. S1; there was a significant increase in IL-28B levels
in chronic HCV patients with high levels of transaminase ALT
and AST compared to those with normal levels (P=0.001. Fig.
S1A and B). In addition, there was no significant difference in IL-
28B levels found between male and female subjects (P=0.13) (data
not shown). Further analysis revealed that there were also no
significant differences in IL-28B levels between the HCV patients
with high and low levels of HCV load, high and normal levels of
total cholesterol (TC) or triglyceride (TG) or infected with 1b and
2a genotypes HCV (data not shown).
Finally, we associated the IL28B polymorphisms with treatment
response in 235 Chinese HCV subjects. The general information,
basic demographic and virological features of the patients was
displayed in Table 3. The RVR, EVR and cEVR rates to
interferon-a2b and ribavirin treatment were 43.4%, 91.1% and
72.3%, respectively.the IL28B CC genotype increased the
proportion of patients who attained cEVR, but not RVR
(P.0.05), in Fig. 3, (cEVR=75.7% for CC vs 38.1% for TC/
TT, P=0.0001). The HCV patients with IL28B CC genotype
significantly increased cEVR, to a less extent, RVR to the
treatment compared to the ones with TC/TT (Fig. 3). Further-
more, the multivariate logistic regression analysis further con-
firmed that the CC genotype was significantly associated with
cEVR compared to TC/TT group (Table 4).
Table 1. Characteristic of 896 study subjects.
Characteristic Persistence Clearance Healthy control P
(n=529) (n=196) (n=171)
Mean age(years)(SD) 50.6(9.1) 51.7 (9.4) 39.6 (9.6) ,0.05
Male(%) 340 (64.3) 101(51.5) m 85(49.7) ? ,0.01
HBsAg status(% positive) 25(4.7) 23(11.7) m none ,0.05
HCV load(6105 IU/ml) 11.2(0.8–31.2) none none
HCV viral genotypes(%)
a
1b 163(57.6) none none
2a 120(42.4) none none
rs12979860
Allele frequency(%)
C 1008(95.3)# 383(97.7) 325(95.0) ,0.05
T 50(4.7) 9(2.3) 17(5.0)
ALT(IU/L) 73.7(66.6) 35.0(30.5) m 24.0(23.9) ,0.05
AST(IU/L) 57.2(45.3) 31.8(23.6) m 23.6(10.9) ,0.05
GGT(IU/L) 87.8(66.9) 46.8(50.7) m 29.8(44.6) ,0.05
TG(mmol/L) 1.4(0.9) 1.5(0.9) 1.5(0.8)
TC(mmol/L) 4.5(1.0) 5.2(1.2) 4.9(1.0)
aHCV viral genotypes was avaliable for 283 individuals in the persistent group.
mP,0.05 and
#P=0.04 persistent vs clearence group;
P,0.05, persistent vs healthy controls;
Quantitative variables are displayed as mean and SD; HCV load are displayed as median and quartile range. ALT, AST, GGT, TG, TC (alanine aminotransferase, aspartate
aminotransferase, glutamyl transpeptidase, triglycerides and total cholesterol).
doi:10.1371/journal.pone.0037054.t001
Table 2. Factors associated with virus spontaneous clearance by logistic regression analysis.
Factors Comparison Adjusted OR* (95% CI) P value Unadjusted OR1 (95% CI) P9 value
Sex Male versus female 1.72 (1.23–2.41) 0.002 1.69 (1.21–2.36) 0.002
rs12979860 genotype C/T+T/T versus C/C 2.13 (1.01–4.45) 0.04 2.07 (1.00–4.31) 0.05
HBsAg Negative versus positive 2.85 (1.56–5.22) 0.001 2.68(1.48–4.84) 0.001
OR, odds ratio; CI, confidence interval.
*Included either rs12979860 genotype and sex, HBsAg with the following covariates: age, HCV load, viral genotype.
1Included rs12979860 genotype and sex, HBsAg in the model without other covariates.
doi:10.1371/journal.pone.0037054.t002
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The data presented here demonstrates that the rs12979860
polymorphism of IL28B locus is closely associated with the
outcomes of HCV infection in Chinese population. In our data,
the normal frequency of rs12979860 T allele was 5% in healthy
control of Chinese population. The frequency of T allele
(rs12979860) was significantly higher among individuals with
persistent HCV than those with cleared infection. Sex, ethnicity,
and coinfections with hepatitis B virus affect spontaneous HCV
clearance [29].
Even after adjustment for the gender and HBV infection in
multivariate logistic regression, the CC and TC/TT of
rs12979860 polymorphisms were still independently associated
with spontaneous clearance and persistent HCV infection,
respectively. The patients with TC and TT genotypes were two
times less effective in their ability to clear HCV relative to patients
with the CC genotypes (Tab. 2).
This is consistent with the recent GWAS, which shown that
IL28B gene variants including rs8099917 are associated with the
spontaneous HCV clearance in European and African American
subjects [17,26,27,30–32].
Intriguingly, the frequency of the protective rs12979860 CC-
genotype is variable across the different ethnic groups; about 95%
in Asia/Chinese population and approximately 55% and 51% in
African and Europeans, respectively [17,31]. Our result using a
relative large cohort confirmed the result in Chinese population
and suggested that IL28B polymorphism may represent a genetic
advantage which confers anti-HCV immunity on the Asia/
Chinese population. It may also provide a genetic explanation
for the previous observations that while they seem to have similar
HCV infection rate as other populations (about 3.2%), the Asian
origin HCV patients appear to achieve better sustained virological
response (SVR) rates when treated with PEG-IFN plus RBV
compared to Caucasians [33]. It will be clinically important to
reveal the detailed mechanism underlying the race influences on
spontaneous virus clearance and antiviral treatment response.
We also demonstrated that the IL28B allele is associated with
response to interferon and ribavirin treatment in Chinese patients
with HCV infection. The patients carrying rs12979860 CC
genotype are more likely to achieve cEVR which are the
important indicator/predictors for the success of treatment in
HCV patients [34–37].
The causative effect of rs12979860 polymorphisms on host
protection against HCV infection is unknown. Since IL-28B
possesses anti-viral activity and the SNPs were adjacent to the
IL28B gene it has been suggested that the variants may associate
with HCV infection by influencing IL-28B gene expression and
protein production [38]. However, to date, little is known about
the role of the gene variants in IL-28B production in HCV
infection. Our results demonstrate that patients with chronic HCV
infection had significantly lower mRNA and serum levels of IL-
28B than subjects who spontaneously cleared the virus and the
healthy controls. Individuals carrying protective rs12979860 CC
genotype in general also tended to have higher IL-28B levels than
those carrying the risk T-alleles in all subjects studied. Further-
more, the IL-28B levels were significantly higher in CC
homozygous than the T homo- or heterozygous (P=0.013) in
the spontaneous clearance group. To support our finding, it has
been reported that the rs8099917 T-protective allele was also
associated with IL-28B mRNA expression in whole blood cells of
healthy individuals [27]. These results suggest that IL28B variants
can impact on IL-28B production which is correlated with host
protection against HCV infection and that reduced IL-28B levels
may be responsible for the chronicity of acute HCV infection.
Figure 1. The association of serum levels of IL-28B with different outcomes of HCV infection and IL28B variants. IL-28B serum levels
were determined by ELISA (A): compares the serum IL-28B levels among the persistent (n=143), clearance (n=56) and healthy control (n=28)
groups. (B): the association of IL-28B levels with rs12979860 alleles in all 227 subjects. (C): the IL28B serum levels in subjects carrying different alleles
in different experimental groups. Data are median (quartile range) and are representative of two experiments.
doi:10.1371/journal.pone.0037054.g001
Figure 2. The association of rs12979860 with AST levels in
chronic HCV patients. The AST levels were determined using a
Synchron LXH20 autoanalyser. The AST levels were higher in patients
carrying the T-allele. Data are mean6SD and representative of two
experiments.
doi:10.1371/journal.pone.0037054.g002
Table 3. Baseline characteristics of the patients treated with
IFN/RBV.
Characteristic Patients
N=235
Age(years), mean(SD) 49.9(7.4)
Gender, Male(%) 169(71.6)
BMI 23.8(2.6)
HCV genotype, n(%)*
1b 127(54.0)
2a 85(36.0)
1b/2a 6(2.5)
HCV load (10
5 IU/ml), median(range) 17(1.5–56)
HCV load.4610
5 IU/ml, n(%) 159(67.4)
rs12979860 CC/TC+TT, n(%) 214/21(91.1/8.9)
RVR, n(%) 102(43.4)
EVR, n(%)* 214(91.1)
cEVR, n(%) 170(72.3)
*Information of HCV genotype was unavailable for 17 patients and 4 patients
who did not complete the treatment.
doi:10.1371/journal.pone.0037054.t003
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which also contains several genes, including IL28A and IL-29
[19,21]. It is likely that the SNP may also affect the function of
other genes in the locus. Indeed, it has been reported that this
variant is associated with increased serum IL-29 and IL-28A/B
levels and the resolution of HCV infection [39,40].
These results suggest that the variations upstream of IL28B gene
may have an impact on the expression and production of all
IFNls, which may explain, at least in part, their profound
association with the outcomes of HCV infection. Therefore, it is
important to further elucidate the mechanism by which the gene
variants regulate the expression of IFNls in HCV infection.
Transaminases are the key clinical assessments for liver function
and immune activation in HCV patients. We found the levels of
transaminases (ALT, AST) were higher in patients with risk
rs12979860-TC or TT than C/C genotype, especially AST. We
also noted that the chronic HCV patients with high serum levels of
ALT and AST aminotransferase also had relatively higher levels of
serum IL-28B production (Fig. S1). The physiopathological
significance of the observations and the relationship between IL-
28B and aminotransferase levels in HCV infection is unknown.
Since IL-28B is involved in anti-virus immunity we reason that
higher aminotransferase and IL-28B levels may reflect the virus-
host interaction and ongoing anti-HCV immune activation in the
hosts and may also be an additional predicator for the outcomes of
chronic HCV infection.
In conclusion, our results suggest that the SNP rs12979860
upstream of IL28B is associated with spontaneous clearance of
HCV and treatment response in Chinese Han population.
Furthermore, chronic HCV infection is associated with a reduced
IL-28B production. Thus, IL-28B may represent a novel
therapeutic agent against HCV and IL28B variations and IL-
28B expression levels may help to predict the outcomes of HCV
infection and treatment. Further research is needed to reveal the
cause-effect of these polymorphisms on host protective immunity
against HCV infection and the mechanism by which HCV
downregulates IL-28B expression.
Supporting Information
Figure S1 The association of serum IL-28B levels with
different levels of ALT/AST in chronic HCV patients.
Serum IL-28B levels were determined by ELISA and ALT/AST
by a Synchron LXH20 autoanalyser. The IL28B levels were higher
in patients with high ALT (.50 IU/ml) (A) or AST (.40 IU/ml)
(B) than those with normal ALT (#50 IU/ml) or AST (#40 IU/
ml). Data are median (quartile range) (n=147) and representative
of 3 experiments.
(TIF)
Figure S2 The relative expression levels of IL28 with
different outcomes of HCV infection and IL28B variants
by qRT-PCR. (A): compares the IL-28A/B expression among
the persistence (n=48), clearance (n=9) and healthy control
(n=17) groups. (B): the association of IL-28A/B expression with
rs12979860 alleles in all 74 subjects. Data are median (quartile
range) and are representative of two experiments.
(TIF)
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